CalciMedica (NASDAQ:CALC) Trading Up 1% – Time to Buy?

by · The Cerbat Gem

CalciMedica, Inc. (NASDAQ:CALC – Get Free Report)’s stock price was up 1% on Monday . The company traded as high as $4.15 and last traded at $4.12. Approximately 4,224 shares changed hands during trading, a decline of 86% from the average daily volume of 31,052 shares. The stock had previously closed at $4.08.

Wall Street Analyst Weigh In

A number of analysts have weighed in on CALC shares. Oppenheimer increased their target price on shares of CalciMedica from $14.00 to $20.00 and gave the company an “outperform” rating in a research report on Wednesday, July 10th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of CalciMedica in a report on Tuesday, August 13th. Finally, Singular Research upgraded CalciMedica to a “moderate buy” rating in a report on Friday, June 28th.

Check Out Our Latest Report on CALC

CalciMedica Stock Performance

The stock has a market capitalization of $43.48 million, a P/E ratio of -1.87 and a beta of 1.27. The business has a fifty day simple moving average of $4.27 and a 200-day simple moving average of $4.65.

CalciMedica (NASDAQ:CALC – Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. On average, sell-side analysts anticipate that CalciMedica, Inc. will post -2.21 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Robert N. Wilson bought 54,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The shares were bought at an average cost of $3.72 per share, for a total transaction of $200,880.00. Following the acquisition, the director now directly owns 364,196 shares in the company, valued at approximately $1,354,809.12. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have bought a total of 65,000 shares of company stock worth $243,120 in the last ninety days. Corporate insiders own 53.30% of the company’s stock.

CalciMedica Company Profile

(Get Free Report)

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.

Featured Articles